Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-6402 in Advanced PD-L1 Positive Solid Tumors
NCT04795713Phase 1Terminated
- Sponsor
- Molecular Templates, Inc.
- Start
- May 2021
- Primary completion
- Oct 2024
- Modality
- Antibody-Drug Conjugates (ADCs), Immunotoxins, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of mt-6402 in solid tumor, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (4 arms), sponsored by Molecular Templates, Inc. Primary endpoints: Safety and Tolerability of MT-6402 at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started May 2021; status: terminated.
02
Drugs
mt-6402
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04795713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04795713.